Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Options in Hypersensitivity Reactions to Chemotherapeutics

Options in Hypersensitivity Reactions to Chemotherapeutics Curr Treat Options Allergy (2018) 5:118–132 DOI 10.1007/s40521-018-0160-x Drug Allergy (MJ Torres Jaén, Section Editor) Options in Hypersensitivity Reactions to Chemotherapeutics Mauro Pagani Address Medical Department ASST di Mantova, Presidio Ospedaliero di Pieve di Coriano, Via Bugatte, 1 Pieve di Coriano, 46024, Mantova, Italy Email: mauro.pagani@asst-mantova.it Published online: 30 January 2018 * Springer International Publishing AG, part of Springer Nature 2018 This article is part of the Topical Collection on Drug Allergy Keywords Chemotherapy hypersensitivity Drug allergy Platinum compound hypersensitivity I I I Taxane hypersensitivity Asparaginase hypersensitivity Desensitization I I Opinion statement Purpose of review Chemotherapeutic drugs still represent a gold standard for the treatment of neoplastic disease. They can induce hypersensitivity reactions and are the third leading cause of fatal drug-induced anaphylaxis in the USA. This article has tried to highlight and summarize the most recent scientific progress concerning risk factors, pathogenesis, diagnosis, and treatment of these reactions. Recent findings Identification of patients at high risk of developing hypersensitivity reactions allows risk stratification to guide clinical decision-making. Therefore, the most recent researches evaluated the possibility to perform risk stratification in case of hypersensitivity reactions to platinum compounds and taxanes. In addition, new data are now available regarding the http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Current Treatment Options in Allergy Springer Journals

Options in Hypersensitivity Reactions to Chemotherapeutics

Current Treatment Options in Allergy , Volume 5 (1) – Jan 30, 2018

Loading next page...
1
 
/lp/springer_journal/options-in-hypersensitivity-reactions-to-chemotherapeutics-a2hJP2Apre

References (99)

Publisher
Springer Journals
Copyright
Copyright © 2018 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Allergology; General Practice / Family Medicine
eISSN
2196-3053
DOI
10.1007/s40521-018-0160-x
Publisher site
See Article on Publisher Site

Abstract

Curr Treat Options Allergy (2018) 5:118–132 DOI 10.1007/s40521-018-0160-x Drug Allergy (MJ Torres Jaén, Section Editor) Options in Hypersensitivity Reactions to Chemotherapeutics Mauro Pagani Address Medical Department ASST di Mantova, Presidio Ospedaliero di Pieve di Coriano, Via Bugatte, 1 Pieve di Coriano, 46024, Mantova, Italy Email: mauro.pagani@asst-mantova.it Published online: 30 January 2018 * Springer International Publishing AG, part of Springer Nature 2018 This article is part of the Topical Collection on Drug Allergy Keywords Chemotherapy hypersensitivity Drug allergy Platinum compound hypersensitivity I I I Taxane hypersensitivity Asparaginase hypersensitivity Desensitization I I Opinion statement Purpose of review Chemotherapeutic drugs still represent a gold standard for the treatment of neoplastic disease. They can induce hypersensitivity reactions and are the third leading cause of fatal drug-induced anaphylaxis in the USA. This article has tried to highlight and summarize the most recent scientific progress concerning risk factors, pathogenesis, diagnosis, and treatment of these reactions. Recent findings Identification of patients at high risk of developing hypersensitivity reactions allows risk stratification to guide clinical decision-making. Therefore, the most recent researches evaluated the possibility to perform risk stratification in case of hypersensitivity reactions to platinum compounds and taxanes. In addition, new data are now available regarding the

Journal

Current Treatment Options in AllergySpringer Journals

Published: Jan 30, 2018

There are no references for this article.